SMTK · SmartKem, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“There is substantial doubt that the Company will be able to pay its obligations as they fall due, and this substantial doubt is not alleviated by management plans.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-09-10 | Lizzio Joseph Christopher |
10% Owner |
Gift↓
|
Common Stock
|
150,000 |
| 2025-09-03 | Keck Barbra |
See Remarks |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Stock Option (right to buy)
|
71,077 |
| 2025-09-03 | de Boer Klaas |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Stock Option (right to buy)
|
22,466 |
| 2025-09-03 | Denis Melisa |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Stock Option (right to buy)
|
22,466 |
| 2025-09-03 | Denbaars Steven |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Stock Option (right to buy)
|
22,466 |
| 2025-09-03 | Jenks Ian |
Director, Chairman & CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Stock Option (right to buy)
|
160,005 |
| 2025-09-03 | Peruvemba Sriram Krishnamurthy |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on September 3, 2025 and on the 3rd date of each month thereafter. |
Stock Option (right to buy)
|
22,466 |
| 2025-05-28 | Keck Barbra |
See Remarks |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
75,660 |
| 2025-05-28 | de Boer Klaas |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
23,915 |
| 2025-05-28 | Denbaars Steven |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
23,915 |
| 2025-05-28 | Jenks Ian |
Director, Chairman & CEO |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company') board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
170,320 |
| 2025-05-28 | Peruvemba Sriram Krishnamurthy |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
23,915 |
| 2025-05-28 | Brown Beverley |
Chief Scientist |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
33,741 |
| 2025-05-28 | Ogier Simon |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
77,656 |
| 2025-05-28 | Watkins Jonathan |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
131,745 |
| 2025-05-28 | Denis Melisa |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The stock option grant was approved by the Compensation Committee of SmartKem, Inc.'s (the "Company") board of directors on April 15, 2025, subject to stockholder approval of an Amendment to the SmartKem, Inc. 2021 Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on May 28, 2025. The option vests as follows: 25% on the date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on May 15, 2025 and on the 15th date of each month thereafter. |
Stock Option (right to Buy)
|
23,915 |
| 2025-03-10 | Watkins Jonathan |
Chief Operating Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-06-14 | Keck Barbra |
See Remarks |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
100,000 |
| 2024-06-14 | Jenks Ian |
Director, Chairman & CEO |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 100% upon date of grant. |
Employee stock option (Right to Buy)
|
16,000 |
| 2024-06-14 | Brown Beverley |
Chief Scientist |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
49,000 |
| 2024-06-14 | de Boer Klaas |
Director |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
20,000 |
| 2024-06-14 | Jenks Ian |
Director, Chairman & CEO |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
165,000 |
| 2024-06-14 | Denis Melisa |
Director |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
20,000 |
| 2024-06-14 | Denbaars Steven |
Director |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
20,000 |
| 2024-06-14 | Ogier Simon |
Chief Technology Officer |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
49,000 |
| 2024-06-14 | Peruvemba Sriram Krishnamurthy |
Director |
Award↑
Filing footnotes — Employee stock option (Right to Buy) (Direct)
The options vested as to 25% upon date of grant with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on July 14, 2024. |
Employee stock option (Right to Buy)
|
20,000 |
| 2024-05-30 | de Boer Klaas |
Director |
Other↓
Filing footnotes — Series A-2 Convertible Preferred Stock (Indirect)
The Series A-2 Convertible Preferred Stock, stated valued equal to $1,000 per share (the "Preferred Stock"), converted automatically into shares of common stock of the Issuer at the conversion price of $8.75 per share on May 30, 2024. The Preferred Stock does not have an expiration date. |
Series A-2 Convertible Preferred Stock
(I)
|
50 |
| 2024-05-30 | de Boer Klaas |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
The Series A-2 Convertible Preferred Stock, stated valued equal to $1,000 per share (the "Preferred Stock"), converted automatically into shares of common stock of the Issuer at the conversion price of $8.75 per share on May 30, 2024. |
Common Stock
(I)
|
5,715 |
| 2024-02-12 | Jenks Ian |
Director, Chairman & CEO |
Gift↓
|
Common Stock
|
500 |
| 2024-02-08 | Jenks Ian |
Director, Chairman & CEO |
Gift↓
|
Common Stock
|
7,200 |
| 2024-01-31 | Denbaars Steven |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. Shares reported reflect a 1-for-35 reverse share split effective September 21, 2023. |
Common Stock
|
100 |
| 2024-01-31 | Keck Barbra |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. |
Common Stock
|
100 |
| 2024-01-31 | Brown Beverley |
Chief Scientist |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. |
Common Stock
|
100 |
| 2024-01-31 | Denis Melisa |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. |
Common Stock
|
100 |
| 2024-01-31 | Jenks Ian |
Director, Chairman & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. Shares reported reflect a 1-for-35 reverse share split effective September 21, 2023. |
Common Stock
|
100 |
| 2024-01-31 | Ogier Simon |
Chief Technology Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. Shares reported reflect a 1-for-35 reverse share split effective September 21, 2023. |
Common Stock
|
100 |
| 2024-01-31 | Peruvemba Sriram Krishnamurthy |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. |
Common Stock
|
100 |
| 2024-01-31 | de Boer Klaas |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Reflects a grant of a stock award issued pursuant to the Issuer's 2021 Equity Incentive Plan, which vested in full upon grant. |
Common Stock
|
100 |
| 2023-11-21 | Denis Melisa |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2023-06-22 | de Boer Klaas |
Director |
Buy↑
Filing footnotes — Series A-2 Convertible Preferred Stock (Indirect)
The Issuer issued its Series A-2 Convertible Preferred Stock (the "Preferred Stock"), at a stated value equal to $1,000 per share. Pursuant to the terms of the Preferred Stock, each share of Preferred Stock is convertible into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), at the election of the holder, at any time following the original issue date at a price of $0.25 per share, subject to price-based anti-dilution adjustments which, if triggered, would result in additional shares of Common Stock being issued upon conversion of the Preferred Stock. The Preferred Stock does not have an expiration date. The purchase was made in a private transaction with the Issuer that closed on June 22, 2023. |
Series A-2 Convertible Preferred Stock
(I)
|
50 |
| 2023-06-22 | de Boer Klaas |
Director |
Buy↑
Filing footnotes — Common Stock Warrants (right to buy) (Indirect)
The warrants were included together with the purchase of the Preferred Stock. Each warrant entitles the holder thereof to purchase one share of Common Stock at an exercise price of $0.25 per share, subject to adjustment. The warrants are currently exercisable and will expire on June 22, 2028. |
Common Stock Warrants (right to buy)
(I)
|
200,000 |
| 2022-12-20 | Keck Barbra |
See Remarks |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. The option vests as to 1/3 of the shares on December 14, 2023 with the remaining shares to vest in equal monthly installments over a period of 24 months commencing January 14, 2024. |
Stock option (right to buy)
|
450,000 |
| 2022-07-08 | de Boer Klaas |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. The option vests as to 25% of the shares on July 8, 2023 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on August 1, 2023. |
Stock option (right to buy)
|
6,000 |
| 2022-07-08 | Keck Barbra |
See Remarks |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. The option vests as to 25% of the shares on July 8, 2023 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on August 1, 2023. |
Stock option (right to buy)
|
6,000 |
| 2022-07-08 | Ogier Simon |
Chief Technology Officer |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's UK Tax-Advantaged Sub-Plan. The option vests as to 25% of the shares on July 8, 2023 with the remaining shares to vest in (i) monthly installments of 937 shares over a period of 35 months commencing on August 1, 2023 and (ii) one installment of 955 shares on August 1, 2026. |
Stock option (right to buy)
|
45,000 |
| 2022-07-08 | Brown Beverley |
Chief Scientist |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. The option vests as to 25% of the shares on July 8, 2023 with the remaining shares to vest in (i) monthly installments of 937 shares over a period of 35 months commencing on August 1, 2023 and (ii) one installment of 955 shares on August 1, 2026. |
Stock option (right to buy)
|
45,000 |
| 2022-07-08 | Jenks Ian |
Director, Chairman & CEO |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. The option vests as to 25% of the shares on July 8, 2023 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on August 1, 2023. |
Stock option (right to buy)
|
150,000 |
| 2022-07-08 | Denbaars Steven |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. The option vests as to 25% of the shares on July 8, 2023 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on August 1, 2023. |
Stock option (right to buy)
|
18,000 |
| 2022-01-27 | King Simon P. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
Reporting person is a partner of Octopus Investments Limited, which is the manager of Octopus Titan VCT Plc. Through his position with Octopus Investments Limited, the reporting person is deemed to control the voting and disposition of the shares of the common stock held by the Octopus Titan VCT Plc. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, Octopus Titan VCT Plc or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Common Stock
(I)
|
986,375 |
| 2022-01-27 | King Simon P. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
Reporting person is a partner of Octopus Investments Limited, which is the manager of Octopus Investments Nominees Limited. Through his position with Octopus Investments Limited, the reporting person is deemed to control the voting and disposition of the shares of the common stock held by the Octopus Investments Nominees Limited. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, Octopus Investments Nominees Limited or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Common Stock
(I)
|
13,625 |